

# ASX Announcement

Medibio Limited – 27 April 2018



## **Medibio to announce third quarter FY18 update and cashflow**

**Sydney, Australia and Minneapolis, MN – 27 April 2018: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF)**, today announced that it will hold a teleconference following the release of its third quarter financial year 2018 update and cash flow report.

An earnings teleconference is scheduled for 10:00am Australian Eastern Standard Time on Friday, 4 May 2018 and will be accessible via the below dial in details and on Medibio's Investor Relations website at <https://medibio.com.au/investors>.

To dial in to the audio only conference call please use either the telephone numbers or the webcast URL provided below.

Australia: +61 3 8488 8990  
United States: +1 562 247 8421  
Access Code: 386 825 244

URL: <https://attendee.gotowebinar.com/register/6839355240278298625>

*After registering, you will receive a confirmation email containing information about joining the webinar.*

Please note that all questions can be submitted via the following email address on [investors@medibio.com.au](mailto:investors@medibio.com.au) and will be addressed throughout the call or specifically at the end of the call if required.

A replay of the webcast will be available after the event and accessible via the webinar address above.

– ENDS –

# ASX Announcement



Medibio Limited – 27 April 2018

## **About Medibio Limited**

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).

## **Further Information:**

### **Medibio Shareholder Enquiries:**

Stephanie Ottens  
Investor Relations Director  
Medibio Limited  
[stephanie.ottens@medibio.com.au](mailto:stephanie.ottens@medibio.com.au)  
T: +61 434 405 400

### **Australian Media Enquiries:**

Peter Taylor  
NWR Communications  
[peter@nwrcommunications.com.au](mailto:peter@nwrcommunications.com.au)  
T: +61 (0) 412 036 231

Website: [www.medibio.com.au](http://www.medibio.com.au)